News

Nuvectis secured worldwide rights, outside specified Asian territories, to develop, manufacture and commercialise Haisco’s drug candidates HSK42360 and HSK39297. Haisco will receive $40m in upfront and near-term payments,

This expands intellectual property protection already in place for Genprex in jurisdictions such as China, Europe, Japan, Russia and the US. Genprex’s Reqorsa is currently in development alongside

The partnership will combine BioArctic’s BrainTransporter technology with an unidentified Lilly drug candidate. BioArctic is set to receive a $30m upfront payment. If the new product progresses successfully,

According to a regulatory filing, Sun Pharma will buy the entire issued and outstanding share capital of Innovcare Lifesciences via a cash transaction. The company expects to close

The approval follows a positive finding in the pivotal IRAKLIA Phase III study, which demonstrated non-inferior efficacy and pharmacokinetics compared with the intravenous (IV) formulation. It also marks

The partnership will bring together Voro Therapeutics’ tumour-activated biologics platform with Alloy Therapeutics’ cluster of differentiation 3 (CD3) antibodies and multispecific engineering capabilities. This joint effort aims to

The deal value comprises an upfront payment and further payments tied to the achievement of future clinical and regulatory milestones. The proposed acquisition will add several anti-inflammatory candidates

The collaboration involves up to $56m in upfront payments to AbCellera for the first two research programmes, with an additional $28m payable if a third programme begins within

Executives from both organisations, including LG AI Research head Woohyung Lim and D&D Pharmatech CEO Seulki Lee, attended the event to formalise the partnership. The project focuses on